Panoramic Capital LLC Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Panoramic Capital LLC bought a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 45,806 shares of the company’s stock, valued at approximately $483,000.

Several other institutional investors also recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. boosted its holdings in ARS Pharmaceuticals by 10.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company’s stock worth $217,000 after acquiring an additional 1,962 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of ARS Pharmaceuticals by 93.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 344,171 shares of the company’s stock valued at $3,631,000 after purchasing an additional 165,950 shares during the period. Rhumbline Advisers boosted its position in ARS Pharmaceuticals by 2.9% during the fourth quarter. Rhumbline Advisers now owns 65,163 shares of the company’s stock worth $687,000 after purchasing an additional 1,824 shares in the last quarter. Peregrine Capital Management LLC purchased a new stake in ARS Pharmaceuticals in the 4th quarter worth $4,469,000. Finally, Compass Capital Corp MA ADV acquired a new position in shares of ARS Pharmaceuticals during the 4th quarter worth about $106,000. 68.16% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Eric Karas sold 10,000 shares of the business’s stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $14.00, for a total transaction of $140,000.00. Following the completion of the transaction, the insider now owns 7,696 shares of the company’s stock, valued at approximately $107,744. The trade was a 56.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Laura Shawver sold 49,600 shares of ARS Pharmaceuticals stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $11.21, for a total value of $556,016.00. Following the sale, the director now directly owns 210,346 shares in the company, valued at $2,357,978.66. The trade was a 19.08% decrease in their position. The disclosure for this sale can be found here. Insiders sold 109,602 shares of company stock valued at $1,311,041 in the last three months. 40.10% of the stock is currently owned by corporate insiders.

ARS Pharmaceuticals Trading Up 0.5%

Shares of ARS Pharmaceuticals stock opened at $13.35 on Wednesday. ARS Pharmaceuticals, Inc. has a twelve month low of $7.55 and a twelve month high of $18.51. The stock has a market capitalization of $1.31 billion, a P/E ratio of -26.18 and a beta of 0.84. The business’s fifty day moving average price is $13.25 and its 200 day moving average price is $12.92.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.35). As a group, sell-side analysts predict that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on SPRY shares. Scotiabank initiated coverage on shares of ARS Pharmaceuticals in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $30.00 target price for the company. William Blair restated an “outperform” rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Oppenheimer began coverage on shares of ARS Pharmaceuticals in a research note on Monday, February 10th. They set an “outperform” rating and a $40.00 price target on the stock. Finally, Raymond James increased their price objective on ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a research note on Tuesday, January 14th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, ARS Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $31.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.